This dataset (NCT00433511-D1) corresponds to information in J Clin Oncol 2018, Sep 1;36(25):2621-2629 PMC6118403.

These data correspond to Tables 1, 2, and A1 and Figures 1, 2, A1, and A2, Adverse Event and Drug Exposure and Discontinuation Sections

Note 8888=no start protocol treatment Step 1

Note 999=missing/unknown

Note 9999=not applicable

Notes for Hazard Ratios Table 2:

-Univariate hazard ratios were stratified by strat1 strat2 strat3 strat4 variables below.

-Multivariate hazard ratios were stratifed by strat3 and strat 4 variables below and adjusted for age (>40 to <65 and >=65 each relative to <=40), erpr variable below, nodal status variable below, tumor size (>2 to <=5 and >5cm each relative to <=2cm), and grade (grade II and grade III each relative to grade I), and dummy variables were included for any covariate with missing values in order to preserve the overall sample size.

Notes for LVEF Information Table A1:

-Typo in Table A1: "(95% CI)" is the "(range)"

-This table summarizes decreases in LVEF which were with or without the presence of Clinical CHF symptoms.

Note for Drug Exposure and Discontinuation Section of manuscript:

The ECOG-ACRIN Biostatistics Center was not provided proofs prior to publication. That first sentence of that section was meant to describe Figure A2 (corresponding to variables bevcns and ttbev in this dataset).

Variable Name	Description
protocol_number	Protocol number
groupuid	Unique patient id (blinded)
reas_no_strt_tx	No start protocol treatment Step 1 1=did not start protocol treatment Step 1 0=started protocol treatment Step 1
reas_no_strt_tx2	No start protocol treatment Arm D Step 2 1=Randomized to Arm C Step 1 and registered to Arm D Step 2 and did not start maintenance bevacizumab in Step 2.
nomaintbev	No start maintenance bevacizumab Arm D Step 2 (this variable reproduces the numbers in the 2nd sentence in the 'Drug Exposure and Discontinuation' section of the manuscript) 1=Randomized to Arm C Step 1 and no start maintenance bevacizumab because either: stopped Step 1 early OR completed Step 1 but did not register to Arm D Step 2 OR registered to Arm D Step 2 and did not start maintenance bevacizumab in Step 2. 0=Randomized to Arm C Step 1 and registered to Arm D Step 2 and started maintenance bevacizumab in Step 2.

elig_this_step_yn	Eligibility Status Step 1 1=classified as ineligible (corresponds to 'Ineligible' row in Figure 1) 0=not classified as ineligible
rxarm2	Treatment Assignment Step 1 A=Arm A B=Arm B C=Arm C
assigned_tx_arm2	Treatment Assignment Step 2 D=Randomized to Arm C in Step 1 and registered to receive maintenance bevacizumab in Step 2 X=Randomized to Arm A or Arm B in Step 1 OR randomized to Arm C in Step 1 but did not register for Arm D (Step 2)
age	Age at randomization (years)
ps	ECOG PS 0=fully active 1=restricted
sex	Sex 1=male 2=female
race	Race 1=White 2=African American 3=Asian 4=Other
tsizecat	Tumor size(cm) 0= <=2 1= >2 to <=5 2= >5
nodecat	Nodal status 0=negative 1=positive
grade	Histologic grade 1=I 2=II 3=III
erpr	ER and PgR Status 1=ER and PgR negative 2=ER and/or PgR positive
rtcat	Primary Surgery and Local Therapy 0=Breast Conserving Surgery(BCS) and WBRT 1=BCS and Partial Breast Irradiation 2=Mastectomy 3=Mastectomy and RT 4=BCS and no WBRT

strat1	ER Positive? 1=yes 2=no
strat2	Lymph Node Involvement 1=negative 2= 1 to 3 positive nodes 3= >=4 positive nodes
strat3	Type of Surgery and planned RT 1=BCS and WBRT 2=BCS and Partial Breast Irradiation 3=Mastectomy no RT 4=Mastectomy and RT
strat4	AC Schedule Planned 1=Classical 2=Dose Dense
dfscns	Invasive Disease-Free Survival (IDFS) indicator 0=censored 1=IDFS event
dfs	Time from Step 1 registration to IDFS event (months)
oscns	Overall Survival (OS) indicator 0=censored 1=death
os	Time from Step 1 registration to OS event (months)
ltfu	Lost to Follow-up Indicator 0=not classified as lost to follow-up 1=lost to follow-up (corresponds to 'Patients who were lost or refused follow-up' row in Figure 1)
chfcns	Clinical (symptomatic) CHF indicator 0=no event 1=Clinical (symptomatic) CHF 2=competing risk event for this analysis Note that 9999 for this variable is for patients who did not start Step 1 protocol treatment or who did not have information on whether cycle 1 was classical or dose dense AC.
ttchf	Time from Step 1 registration to Clinical (symptomatic) CHF (months)
bevcns	Bevacizumab Discontinuation Indicator 1=registered to Arm B or C Note that 9999 here refers to patients who were randomized to Arm A.
ttbev	Time from Step 1 registration to bevacizumab discontinuation (months)
lvefbsl_c5	Baseline lvef (among those with baseline and end of cycle 4(D1C5) lvef)
lvefc5	Lvef at end of cycle 4(D1C5)
b_c5c	Baseline to end of cycle 4 (D1C5) 0=no 1=yes, lvef decrease >10% from baseline
b_c5lvef	Baseline to end of cycle 4(D1C5) 0=no 1=yes, lvef decrease >10% from baseline to below the LLN

lvefst1	Lvef at EOC (end of Step 1)
b_st1c	Baseline to end of chemotherapy(EOC)(end of Step 1) 0=no 1=yes, lvef decrease >10% from baseline
b_st1lvef	Baseline to end of chemotherapy (EOC)(end of Step 1) 0=no 1=yes, lvef decrease >10% from baseline to below the LLN
lvefc9	Lvef at end of cycle 9
b_c9c	baseline to end of cycle 9 (Arm D only) 0=no 1=yes, lvef decrease >10% from baseline
b_c9lvef	Baseline to end of cycle 9 (Arm D only) 0=no 1=yes, lvef decrease >10% from baseline to below the LLN
lvefc15	Lvef at end of cycle 15
b_c15c	Baseline to end of cycle 15 (Arm D only) 0=no 1=yes, lvef decrease >10% from baseline
b_c15lvef	Baseline to end of cycle 15 (Arm D only) 0=no 1=yes, lvef decrease >10% from baseline to below the LLN
lvef12m	Lvef at 12 months post randomization
b_12mc	Baseline to 12 months post randomization 0=no 1=yes, lvef decrease >10% from baseline
b_12mlvef	Baseline to 12 months post randomization 0=no 1=yes, lvef decrease >10% from baseline to below the LLN
lvefst2	Lvef at end of bevacizumab (EOB)(end of Step 2) (Arm D only)
b_st2c	Baseline to end of bevacizumab (EOB)(end of Step 2) (Arm D only) 0=no 1=yes, lvef decrease >10% from baseline
b_st2lvef	Baseline to end of bevacizumab (EOB)(end of Step 2) (Arm D only) 0=no 1=yes, lvef decrease >10% from baseline to below the LLN
lethalae	Lethal adverse events during or within 30 days of protocol treatment 1=AML 2=Infection 3=CNS Ischemia or hemorrhage 4=Pulmonary hemorrhage or fibrosis 5=Liver failure 6=Thrombosis or embolism 7=Colitis 8=Sudden death 9=Hypotension